OXON Technologies launches globally to deliver world-first fuel saving, emissions reduction fuel innovation
'We have created the building block for a new generation of cleaner fuels. Our patented technology is already transforming the role of internal combustion engines' — Chief Executive of OXON™ Technologies, Andrew Lowenstein
HENDERSON, NV, UNITED STATES, January 27, 2025 / EINPresswire.com / -- OXON™ Technologies launches OXON™Drive and OXON™Build products based on its patented OXONtech™ process that dramatically cuts emissions and fuel consumption for combustion engines. By reducing the activation energy required for combustion in liquid fuels, OXONtech™ products enable cleaner and more efficient combustion directly cutting carbon emissions by over 20% and fuel consumption by over 10%. With tens of thousands of vehicles already using OXONtech™ products, the firm is now scaling production to meet demand globally.
The technology
OXONtech™ is a patented method for inducing permanent dipoles (molecular charges) into proprietary OXON™ products. When these OXON™ products are blended into liquid fuels at refineries, central fueling stations or vehicle tanks, they modify the fuels to accelerate and transform combustion.
1. OXON™ products introduce nano-micelles (charged micro-clusters of organic molecules) that disperse amongst the hydrocarbon molecules of fuel.
2. OXON™ nano-micelles contribute free radical particles that create cascade reactions with lower energy activation barriers thus promoting faster combustion and reducing fuel consumption.
3. OXON™ nano-micelles also create complexes with oxygen. During combustion, these minimize heat absorbing oxygen-nitrogen collisions, thus reducing NOx emissions which are harmful to air quality and human health.
Impact
Addressing the environmental impact of internal combustion engines, OXONtech™ powered fuels have a transformative effect on the emissions profile of engines which emit up to 90% less particulate matter, 60% less NOx emissions, and 21% less CO2e emissions.
OXON™ products are easily integrated into existing fleet fueling operations. With over ten million hours of run time globally in 2024, OXON™ Technologies' customers have displayed an average of 10% less fuel consumption and 97% less engine downtime from emissions faults when using OXON™ products.
Expanding customer base
Now scaling to meet global demand, OXON™ Technologies is currently supporting fleets that operate over 260,000 vehicles across the United States, Europe, and Africa in sectors including logistics, commuter transportation, mining, and construction.
One customer, NYSE listed Sterling Infrastructure Inc.'s portfolio businesses Petillo, has used OXON™Build on 330 heavy vehicles in its fleet and demonstrated a 10.5% average fuel reduction over the course of 2024. Other customers include some of the world's largest transport and construction fleets.
Chief Executive of OXON™ Technologies, Andrew Lowenstein said: 'We have created the building block for a new generation of cleaner fuels. Our patented technology modifies hydrocarbon fuels at the molecular level to enhance combustion, and our drop-in products are already transforming the role of internal combustion engines in the mix for decarbonization, efficiency improvement and fleet optimization. Once broadly adopted, OXON™ products each year could prevent 1.7 bn tons of carbon from being emitted across the globe, reduce spending on fossil fuels by $525 bn and contribute towards saving millions of lives currently lost to fine-particulate matter (PM2.5) & NOX pollution.'
ENDS
About OXONtech
OXON™ Technologies, an American technology firm with worldwide presence, is focused on developing world leading solutions that reduce emissions and fuel consumption. After developing and patenting the OXONtech™ production process, the company's Nevada-based team has launched OXON™Drive and OXON™Build products that can be easily integrated into existing fleet operations and are currently used in transport vehicles and construction equipment across five continents.
Andrew Turner
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
Commercial trial demonstrates SaFeGuard's™ effectiveness in processing opportunity crudes HOUSTON, August 20, 2025--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. "We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations," said Ketjen's Chief Commercial Officer Henri Tausch. "This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers." "SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon," said David Leach, Vice President and General Manager, FCC at Ketjen. "It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement." Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit View source version on Contacts Media Contact: Jennifer Albert, MediaRelations@ Sign in to access your portfolio
Business Wire
2 hours ago
- Business Wire
Ketjen Introduces New Breakthrough Catalyst Technology that Effectively Mitigates the Effects of Iron Poisoning in FCC Units
HOUSTON--(BUSINESS WIRE)--Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing has launched SaFeGuard™, a new catalyst technology designed to address iron (Fe) poisoning in FCC units. In a recent 30-day full commercial trial, SaFeGuard™ demonstrated a 77% improvement in accessibility with a 50% inventory replacement enabling an increase in unit activity, improved bottoms cracking, and ability to process heavy iron-rich feedstocks. Further testing and predictive modeling suggest that a full 100% inventory changeout could yield up to a 130% increase in accessibility delivering additional improvement in performance. SaFeGuard™ delivers a step change in the contaminant Fe and calcium (Ca) tolerance window by minimizing the Eutectic formation, thereby keeping catalyst pores open. This enables higher activity levels and furthers bottoms cracking, ultimately uplifting profit margins. 'We've developed a powerful, safe and sustainable solution that addresses iron poisoning and will increase profitability for our customers by allowing for lower-cost feeds and more efficient operations,' said Ketjen's Chief Commercial Officer Henri Tausch. 'This new technology is the culmination of decades of research aimed at developing industry leading iron and calcium tolerant catalysis and illustrates our commitment to developing innovative solutions that support the evolving needs of our customers.' 'SaFeGuard™ is a great option for refiners who are taking advantage of opportunity crudes and even bio feeds because it is just as effective in combating additional contaminants including nickel, vanadium, calcium, sodium, and silicon,' said David Leach, Vice President and General Manager, FCC at Ketjen. 'It can be used to process iron-rich feedstocks including heavy, resid, tight oil and renewable feeds, and it's also great for units facing accessibility limitations because it requires less frequent catalyst replacement.' Ketjen's next generation SaFeGuard™ technology is currently available for use by refiners around the globe. Contact us to learn more about how you can unlock the full potential of your FCC unit. About Ketjen Ketjen is a provider of advanced catalyst solutions to leading producers in the petrochemical, refining and specialty chemicals industries. From fluidized catalytic cracking to clean fuels solutions to hydro-processing to organometallics and curatives, Ketjen delivers safe and reliable solutions that increase production performance and business value. A wholly owned subsidiary of Albemarle Corporation (NYSE: ALB), Ketjen Corporation is headquartered in Houston, Texas, and serves global customers through operations in 25 markets. For more information, visit
Associated Press
2 hours ago
- Associated Press
AcCELLerated Biologics to Distribute RegenaLase™ Laser System from IPG Medical Corporation Across the United States
Jupiter, FL August 20, 2025 --( )-- AcCELLerated Biologics, LLC, a leading distributor of regenerative medicine technologies, today announced an exclusive agreement with IPG Medical Corporation, a wholly owned subsidiary of IPG Photonics Corporation, to distribute the RegenaLase™ Laser System throughout the United States. This new dual-wavelength laser platform is engineered to treat musculoskeletal soft tissue, including meniscus cartilage and inflammation. The RegenaLase system features two advanced laser modalities: 1550 nm erbium fiber laser for minimally invasive cartilage surgery 980 nm diode laser for non-invasive photobiomodulation therapy This dual functionality enables physicians to provide both in-office pain relief and advanced cartilage treatment — all from a single, compact, and versatile device. 'This partnership with IPG Medical marks a major milestone in regenerative medicine,' said Steve Whyte, CEO and Founder of AcCELLerated Biologics. The 'RegenaLase system merges laser innovation with non-invasive phototherapy, giving physicians powerful tools to reduce pain and restore cartilage—without the complications of traditional surgery. At AcCELLerated Biologics, we remain committed to being first to market with cutting-edge solutions that empower our physicians to deliver exceptional care to their patients.' 'I recently attended a cadaver training course at RMTI in Jupiter, Florida, to learn in detail how the RegenaLase Laser can treat musculoskeletal pathologies. This laser technology is poised to be a game changer,' said Joshua G. Hackel, MD, FAAFP, RMSK, CAQSM, Sports Medicine Specialist at the Andrews Institute for Orthopaedics and Sports Medicine. 'We are looking forward to conducting a prospective study utilizing the RegenaLase Laser System to treat knee osteoarthritis at the Andrews Research and Education Foundation in Gulf Breeze, Florida.' 'I have been fortunate in my career to be involved in some groundbreaking technology and techniques. It has allowed me to help many patients heal from their injuries,' said Michael A. Scarpone, D.O. Scarpone Sports Regenerative, Steubenville, Ohio. 'The RegenaLase laser is one of those technologies that has the potential to help a great many patients with knee osteoarthritis and beyond. I am excited to be participating in this project — past, present, and future.' Clinical studies have demonstrated the effectiveness of RegenaLase when paired with optional biologic adjuncts such as Platelet-Rich Plasma (PRP), adipose tissue, and bone marrow aspirate. Patients have shown significant reductions in pain and measurable improvements in joint function. Designed with ergonomics and flexibility in mind, the system is well-suited for both surgical suites and office-based settings, enabling highly personalized treatment protocols, based on delivering multiple, separated microscopic columns of coagulation to the target tissue. 'We're excited to partner with AcCELLerated Biologics to expand access to the RegenaLase system across the United States,' said Alexander Vybornov, IPG Medical Sr. Director of Partnerships & Commercialization. 'With our expertise in laser innovation and AcCELLerated Biologics' strong clinical support and distribution network, more physicians will be empowered to adopt this advanced laser therapy for pain management and advanced musculoskeletal tissue treatment.' The RegenaLase system is FDA-cleared for coagulation of soft tissue including meniscus cartilage, and temporary relief of pain via tissue heating. About AcCELLerated Biologics, LLC AcCELLerated Biologics is a premier distributor of regenerative medicine devices and biologics, dedicated to equipping physicians with the most advanced technologies to improve patient outcomes. Learn More: Media Contact: Sharon Bruneau [email protected] Contact Information: AcCELLerated Biologics Sharon Bruneau +1 (407) 230-3290 Contact via Email Read the full story here: AcCELLerated Biologics to Distribute RegenaLase™ Laser System from IPG Medical Corporation Across the United States Press Release Distributed by
